Business Combinations (Narrative) (Details)	3 Months Ended		12 Months Ended
	Apr. 03, 2022 USD ($)	Apr. 04, 2021 USD ($) $ / shares	Jan. 02, 2022 USD ($) employees shares	Sep. 17, 2021 $ / shares	Jan. 03, 2021 USD ($)
Business Acquisition [Line Items]
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions	1 year
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 49,828,000	$ 3,124,000	$ 57,996,000		$ 2,953,000
Total transaction costs	(20,500,000)	(4,400,000)
Goodwill	7,367,284,000		7,416,584,000
Business Combination, Contingent Consideration, Liability, Current	1,100,000		1,300,000
Business Combination, Contingent Consideration, Liability, Noncurrent	48,700,000		56,700,000
Interest Expense	28,388,000	14,126,000
Business Combination, Contingent Consideration, Liability	49,800,000		$ 58,000,000
Business Combination, Acquisition Related Costs	$ 20,500,000	4,400,000
Fiscal Year 2022 Acquisitions [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	5 years
Oxford Immunotec [Member]
Business Acquisition [Line Items]
Entity Number of Employees | employees			275
Foreign Currency Transaction Gain (Loss), before Tax		(5,400,000)
Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments			$ (183,000)
Business Combination, Consideration Transferred			981,698,000
Cash Acquired			(195,010,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets			72,104,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			26,507,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets			15,564,000
Cash paid to the shareholders			1,128,584,000
Business Combination, Consideration Transferred, Liabilities Incurred			2,910,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years 3 months 18 days
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	$ 45,031,000
Goodwill	550,023,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	61,960,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			981,698,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable			$ 0
Nexcelom Bioscience [Member]
Business Acquisition [Line Items]
Entity Number of Employees | employees			130
BioLegend [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue		1,385,114,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			$ 91,700,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			25,800,000
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments			0
Business Combination, Consideration Transferred			5,688,964,000
Cash Acquired			(292,377,000)
Cash Acquired from Acquisition			(292,400,000)
Business Acquisition, Cost of Acquired Entity, Consideration Paid in Cash			3,300,000,000
Business Acquisition, Cost of Acquired Entity, Consideration Paid in Common Stock			2,600,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets			184,704,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			147,200,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets			$ 9,330,000
Entity Number of Employees | employees			700
Cash paid to the shareholders			$ 3,336,115,000
Business Combination, Consideration Transferred, Liabilities Incurred			$ 6,857,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			16 years 3 months 18 days
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value			$ 0
Goodwill			3,510,710,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			38,239,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			$ 5,688,964,000
Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax		$ 370,624,000
Business Acquisition, Pro Forma Earnings Per Share, Basic | $ / shares		$ 2,940
Business Acquisition, Pro Forma Earnings Per Share, Diluted | $ / shares		$ 2,930
Business Acquisition, Share Price | $ / shares				$ 187.56
Stock Issued During Period, Shares, Acquisitions | shares			14,066,799
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable			$ 2,638,369,000
Acquisition-related stock compensation expense	7,500,000
Cash Acquired from Acquisition			292,400,000
Shandong Meizheng [Member]
Business Acquisition [Line Items]
Compensation Expense, Excluding Cost of Good and Service Sold		$ 5,400,000
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,960,267,000		1,970,350,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	5,407,017,000		5,446,234,000
Core Technology [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	290,089,000
Core Technology [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			782,400,000
Customer Relationships [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	141,670,000
Customer Relationships [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			1,714,800,000
Trade Names [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	39,626,000
Trade Names [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			38,000,000
United States of America, Dollars | Fiscal Year 2022 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	13,500,000
United States of America, Dollars | Oxford Immunotec [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			590,900,000
United States of America, Dollars | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			1,200,000,000
United States of America, Dollars | Nexcelom Bioscience [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			267,300,000
United States of America, Dollars | BioLegend [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			5,700,000,000
United States of America, Dollars | Fiscal Year 2021 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	$ 318,600,000
Amortization of intangible assets recognized in acquisition [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			47,000,000
Amortization of fair value adjustment to acquired inventory [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			$ 16,600,000